Linsitinib (OSI-906) for the treatment of Adult and Pediatric Wild Type Gastrointestinal Stromal Tumors, a SARC Phase II study

PURPOSE: Most GISTs have activating mutations of KIT, PDGFRA, or uncommonly BRAF. Fifteen percent of adult and 85% of pediatric GIST are wild type (WT), commonly having high expression of IGF-1R and loss of succinate dehydrogenase (SDH) complex function. We tested the efficacy of linsitinib, an oral...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Cancer Res
Päätekijät: von Mehren, Margaret, George, Suzanne, Heinrich, Michael C., Schuetze, Scott M., Yap, Jeffrey T., Yu, Jain Q., Abbott, Amanda, Litwin, Samuel, Crowley, John, Belinsky, Martin G., Janeway, Katherine A., Hornick, Jason L., Flieder, Douglas B., Chugh, Rashmi, Rink, Lori A., Van den Abbeele, Annick A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2019
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7856429/
https://ncbi.nlm.nih.gov/pubmed/31792037
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-1069
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia